Cartesian Growth Corp II (REEWF)

Cartesian Growth Corporation II (REEWF represents the common shares) is a special purpose acquisition company that never acquired anything. It raised money in 2022 with the mandate to identify and merge with a private business, take it public, and return it to investors as a newly public entity. That is the entire purpose of a SPAC. Cartesian did not succeed. After three charter extensions and roughly four years of searching, the Nasdaq delisted it for non-compliance with SPAC listing rules, and it now trades on the OTC Pink market as a penny stock. There is no business, no revenue, and no operations — only a shrinking cash reserve allocated to legal and administrative overhead.

Why SPACs fail

The structural issue is simple: SPACs are hungry for deals, sponsors are paid by closing a deal (not by picking a good one), and the pool of companies willing to take SPAC capital has shrunk as investor skepticism has grown. When a sponsor cannot close a merger, the path is either to extend the deadline (burning cash on extensions and redemptions as shareholders cash out) or to liquidate and return whatever cash remains to shareholders, minus fees. Cartesian chose extensions, three times, until the Nasdaq stopped tolerating it. Most shareholders who bought the IPO have long since redeemed their shares for cash and exited.

REEWF shares represent an ownership stake in a cash pool that is shrinking monthly. The company owes management fees, legal bills, and administrative costs. Shareholders do not receive dividends because there is no earnings and every dollar of capital is earmarked either for a potential acquisition or for liquidation proceeds. This is “dead money” — capital tied up with no return, no business generating value, and a declining per-share value as costs accrue and redemptions shrink the float.

What shareholders now hold

A REEWF shareholder holds a claim on the trust account’s remaining $37.75 million divided among the remaining shares outstanding — the only residual value. If the company liquidates, shareholders receive their pro-rata share of trust capital, after legal and administrative wind-down costs. That liquidation value-per-share is worth less than cash in bank because of the fees still to be paid. The warrants (the right to buy shares at a fixed strike price) will almost certainly expire worthless; no rational shareholder would exercise the right to buy shares in a liquidating shell company.

The cautionary lesson Cartesian illustrates is that capital is only as good as the opportunity to deploy it. A $230 million SPAC sounds impressive until it spends four years failing to find a target, and suddenly that capital represents a sunk cost, not an asset. For investors, this is why SPAC performance has diverged so sharply since 2021 — early-vintage SPACs with strong sponsors found excellent targets; later ones, as scrutiny tightened and deal flow slowed, struggled to deploy capital before shareholders redeemed. Cartesian is a cautionary data point: a blank check that found nothing to write.